The VERTIS-CV Trial

Key messages

• Ertugliflozin is noninferior to placebo for reduction of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
• The effects, especially on heart failure, are consistent with the benefits seen with the class of SGLT2 inhibitors.